Quest Diagnostics adds Los Angeles lab network to its stable

Quest Diagnostics sign
In taking over some of CLA's assets, Quest will add several patient service centers to its network in southern California. (Ed Uthman/CC BY-SA 2.0)

Quest Diagnostics has acquired certain assets of California Laboratory Associates (CLA), a clinical lab network in the greater Los Angeles area, for an undisclosed sum.

With the acquisition, Quest will add several CLA patient service centers to its network, expanding its reach in southern California.

"This acquisition will deepen our presence and ability to serve the region, while advancing our strategy to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions,” said Quest CEO Steve Rusckowski in a statement.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

RELATED: Quest Diagnostics rolls out more accurate, nonfasting cholesterol tests

Caregivers and the lab at Providence St. Joseph Medical Center in Burbank previously supported CLA’s operations and patients. While Quest is taking over some of CLA’s assets, Providence St. Joseph will continue to run its lab for hospital patients and certain outside physician services, according to the statement.

"Providence caregivers who have supported CLA's operations and patients have provided exemplary service across the greater Los Angeles area, helping to care for patients and coordinating with provider offices to ensure quality laboratory services," said Erik Wexler, CEO of Providence St. Joseph Health, Southern California Region. "We are confident Quest Diagnostics will carry on the high standards our caregivers set in providing quality and compassionate care."

In July, Quest picked up a pair of Texas laboratory businesses and set up a national “center for excellence” for cancer precision diagnostics, strengthening its presence in the southwestern U.S.

“This transaction will not only accelerate Quest's growth in cancer diagnostics, but also holds the promise of improving care for patients with cancer in Texas and the entire United States,” Rusckowski said at the time.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.